This month we published a modular update to our health technology evaluations manual focusing on how we consider the effect of health technologies on health inequalities. The update is designed to ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510] Technology appraisal guidance Abatacept for treating active ...

For further information on the guideline development process, please see how we develop NICE guidelines ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

Erdafitinib (Balversa, Johnson & Johnson) is indicated for 'the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations ...

Erdafitinib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic urothelial cancer with susceptible FGFR3 genetic alterations in adults after at ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Personalised home hazard assessments and interventions will help to prevent older and at-risk people from suffering from falls, according to new NICE guideline ...

We know that AI is vital for the NHS to deliver reduced waiting times and faster diagnoses for patients, which is why the health service plays such a vital role in supporting technologies like DERM by ...

An artificial intelligence system for potential skin cancer has been conditionally recommended for use in the NHS for the next three years while further evidence is collected. Personalised assessments ...